期刊文献+

120例小肝癌手术切除的临床分析 被引量:1

下载PDF
导出
摘要 目的总结120例小肝癌手术治疗的效果。方法回顾分析本所1998年1月至2007年12月手术治疗的120例小肝癌的情况。结果全组无手术死亡。术后1、3、5年生存率分别为95.2%、72.2%、55.2%。术后1、2、3年复发率分别为13.6%、32.1%、43.2%。结论手术切除是小肝癌首选的治疗方法,对左叶或表浅的小肝癌作非规则切除,对中央型、有包膜深在小肝癌作简化肝切除,手术切除效果满意。
出处 《中外医疗》 2008年第16期132-,共1页 China & Foreign Medical Treatment
  • 相关文献

参考文献3

二级参考文献8

  • 1吴福生,赵文和,梁廷波,任国平,马志敏,滕理送.影响3 cm以下小肝癌患者术后生存因素的观察[J].中华外科杂志,2005,43(9):579-583. 被引量:13
  • 2Ochiai T,Sonoyama T,Ichikawa D,et al.Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis[J].J Cancer Res Clin Oncol,2004,130(4):197 -202.
  • 3Shimada M,Gion T,Hamatsu T,et al.Evaluation of major hepatic resection for small hepatocellular carcinoma[J].Hepatogastroenterology,1999,46(25):401 -406.
  • 4Shimozawa N,Hanazaki K.Longterm prognosis after hepatic resection for small hepatocellular carcinoma[J].J Am Coll Surg,2004,198(3):356 -365.
  • 5Wayne JD,Lauwers GY,Ikai I,et al.Preoperative predictors of survival after resection of small hepatocellular carcinomas[J].Ann Surg,2002,235 (5):722-730.
  • 6Regimbeau JM,Kianmanesh R,Farges O,et al.Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma[J].Surgery,2002,131 (3):311-317.
  • 7Ko S,Nakajima Y,Kanehiro H,et al.Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy.Result of multivariate analysis[J].Ann Surg,1996,224(5):591 -595.
  • 8Hu RH,Lee PH,Chang YC,et al.Prognostic factors for hepatocellular carcinoma < or = 3 cm in diameter[J].Hepatogastroenterology,2003,50 (54):2043-2048.

共引文献19

同被引文献16

  • 1Kirchner G, Kirovski G, Hebestreit A, et al. Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany [J]. Int J Clin Exp Meal, 2010,3(2):169-179.
  • 2Wang J, Xu L B, Liu C, et al. Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center [ J ]. World J Surg, 2010,34( 10):2434-2441.
  • 3Llovet J M, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med, 2008,359(4):378-390.
  • 4Cheng A L, Kang Y K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase Ⅲ randomised, double-blind, placebo-controlled trial [ J ]. Lancet Oncol, 2009,10 ( 1 ) : 25-34.
  • 5Yau T, Yao T J, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials [J]. Cancer, 2008,113(10):2742-2751.
  • 6Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner [J]. Liver Int, 2009,29(4):478-480.
  • 7Marrero J A, Kado M, Bronowicki J P. The challenge of prognosis and staging for hepatocellular carcinoma [J]. Oncologist, 2010, 15 (Suppl 4) :23-33.
  • 8Pascual S, Zapater P, Such J, et al. Comparison of staging systems to predict survival in hepatocellular carcinoma [J]. Liver Int, 2006, 26(6) : 673-679.
  • 9Hsu C Y, Hsia C Y, Huang Y H, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models [J]. Cancer, 2010,116(12) : 3006-3014.
  • 10Camma C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems [J]. Aliment Pharmacol Ther, 2008,28(1 ):62-75.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部